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INTRODUCTION 
 
 
CHAPTER 1.  
 
Transcriptional regulation of gene expression 
 
The development of eukaryotic organisms requires the differential transcription of thousands of 
genes in precise spatial and temporal patterns. Cells accomplish this task by means of a limited 
repertoire of activators which link related signaling pathways and integrate diverse regulatory cues 
employing the principle of cooperativity and transcriptional synergy on regulatory elements along 
the DNA (Michael Carey, 1998). 
 
 
1. Transcription factors 
 
Any protein that is needed for the initiation of transcription, but which is not itself part of RNA 
polymerase is defined a transcription factor. They can be divided in three main classes: basal factors 
interact with RNA polymerase at the startpoint; activators recognize specific short response 
elements (REs) in the promoter or enhancers increasing the frequency of transcription; coactivators 
provides a connection between activators and the basal apparatus. Transcription factors can be 
furtherly grouped into classes that use related structural motif for recognition: helix-turn-helix 
(HTH) proteins, the homeodomains, zinc finger proteins, the steroid receptors, leucine zipper 
proteins and helix loop helix proteins.  
For example the homeodomain is a DNA-binding domain of 60 amino acids that has three α-
helices; it was firstly found in homeotic genes which are one of three groups of genes which control 
D. melanogaster development; in particular these genes determine the identity of body structures, 
i.e. impose the program that determines the unique differentiation of each segment. Sequence related 
to the homeodomain  are found in several types of animal transcription factors, for example in the 
paired box transcription factors (Pax family) which control embryonic development within a variety 
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of cell lineages. The leucine zipper (ZIP), instead, is an amphipathic helix that dimerizes forming 
the bZIP motif  in which two adiacent basic regions bind inverted repeats in DNA. This motif is 
found in the AP-1 protein, a transcription factor composed of Jun and Fos family members; diverse 
combinations of AP-1 components mediate various biological processes, for example the 
heterodimer AP-1cJun-cFos is required for the expression of activin-responsive organizer genes (Sung-
Young Lee et al., 2011).  
As last protein domain example, the helix loop helix motif is a stretch of 40-50 amino acids 
containing two amphipatic α-helices separated by a linker region (the loop) of varying length which 
role is probably important for allowing the freedom for the two helical regions to interact 
indipendently of one another. Proteins belonging to this class have important roles in differentiation 
and development as shown by MyoD which is involved in the formation of muscle cells together 
with several basic HLH proteins; MyoD interaction with the non basic HLH Id prevents 
myogenesis, while MyoD association with basic HLH E12 or E47 proteins is the trigger for muscle 
differentiation in that the complex activate transcription (Lewin Gene VIII, Gary Carlson Editor). 
The overall structure of transcription complexes is that of a controlled mechanisms with a modular 
architecture both in proteins structure and in regulatory DNA elements which they bind to. The 
modular structure in proteins is found in distinct regions dedicated to different functions: a DNA-
binding domain that directs the protein to a specific DNA site, a multimerization domain that allows 
assembly of either homo- or hetero-multimers, and an effector domain that can modulate the rate of 
transcription (Menie Merika et al., 2001). These domains act as a bridge between the basal 
transcription apparatus and activators; the former is infact not adequate to initiate more than low 
levels of transcription which significant amount need transcriptional activators; these are in turn 
targets of multiple signaling pathways providing notions on how cells adapt to external cues by 
controlling gene expression. 
 
 
2. Cis-regulatory elements 
 
The elements on which the transcriptional apparatus assembles thus responding by means of gene 
expression to external environment is made of cis-acting control elements that specify the location, 
timing and magnitude of the response (Menie Merika et al., 2001).  
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Each gene has in fact a particular combination of regulatory elements, whose nature, number and 
spatial arrangement determine the gene’s unique pattern of expression: in that consist the above 
mentioned modularity in DNA elements. They can be simply divided in two main categories: 
promoters which comprise core promoter and proximal promoter elements, and distal regulatory 
elements made up of enhancer, silencers, insulators, or locus control regions. 
 
 
2.1 Promoter and upstream promoter elements 
 
The “gene promoter” is a collection of cis-regulatory elements required for initiation of 
transcription; three classes of promoters drive different classes of genes. Polymerase I promoters are 
used by genes that encode ribosomal RNAs, polymerase II promoters are used by genes that are 
transcribed to yield mRNAs and hence, proteins; polymerase III promoters are used by genes that 
encode small RNAs. 
Pol II core promoter is an approximately 60 bp DNA sequence overlapping the transcription start 
site (+1) that serves as the recognition site for RNA polymerase II and general transcription factors.  
Core promoters elements consist of: BRE, TATA box, Inr-Initiator, MTE-motif ten element, DPE-
Downstream promoter element and DCE-downstream core element (Fig. 1). 
 
 
 
  
 
 
Fig. 1: Core promoter elements.  
Metazoan core promoters are composed of a number of elements that may include a TATA box, an 
Initiator element (Inr), a Downstream Promoter Element (DPE), a Downstream Core Element (DCE), 
a TFIIB-Recognition Element (BRE), and a Motif Ten Element (MTE). The human consensus 
sequence of these elements, their relative positions, and the  transcription factors that bind them are 
shown. The DCE is shown on a separate core promoter for illustration purposes only. Although the 
DCE can be present in promoters containing a TATA box and/or Inr, it presumably does not occur 
with a DPE or MTE (Glenn A. et al., 2006). 
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The TATA box is an AT reach region whose consensus sequence is TATAAA, located about 25-30 
nt upstream of the transcription start site, but even upstream promoter sequences that resemble 
TATAAA may be functional TATA motif.  
In humans it was found that about 32% of 1031 potential promoter regions contain a putative TATA 
box motif. Recognition of the TATA box is conferred by the TATA-binding protein (TBP), a small 
protein of 30 kDa, which constitutes the general transcription factor TFIID together with other 
subunits called TAFs (for TBP associated factors).  
The BRE sequence is a TFIIB binding site that is located immediately upstream of some TATA 
boxes; in vitro transcription experiments with purified basal transcription factors revealed that the 
BRE facilitates the incorporation of TFIIB into productive transcription initiation complexes 
(Lagrange et al. 1998, Suzuki et al. 2001).  
The Inr encompasses the transcription start site and was identified in a variety of eukaryotes 
(Breathnach and Chambon, 1981). 
Inr elements are found both in TATA-containing as well as TATA-less core promoters. The 
consensus for the Inr in mammalian cells is Py-Py(C)-A-N-T/A-Py-Py. The A+1 position is 
designated at the +1 start site because transcription commonly initiates at this nucleotide. More 
generally, however, transcription initiates at a single site or in a cluster of multiple sites in the 
vicinity of the Inr (and not necessarily at the A+1 position). 
Different sequence-specific DNA-binding factors have been found to interact with the Inr, there is 
considerable evidence that TFIID binds to the Inr in a sequenc specific manner (Roy et al., 1991). 
Aside from them, it has also been observed that RNA Polymerase II is able to recognize the Inr and 
to medite transcription in an Inr-mediated manner in the absence of TAFs (Carcamo et al., 1991; 
Weis and Reinberg, 1997). These results suggest that recognition and interaction with the Inr occurs 
at different steps in the transcription process. 
The DPE is located precisely at +28 to +32 relative to the A+1 position; it was identified as a 
downstream core promoter-binding site for purified Drosophila TFIID (Burke and Kadonaga, 1996). 
TFIID binds cooperatively to the Inr and DPE motifs, as mutation of either the Inr or the DPE 
results in loss of TFIID binding to the core promoter (Burke and Kadonaga, 1996). Naturally 
occurring in TATA-less core promoters, mutation of the DPE motif results in a 10- to 50-fold 
reduction in basal transcription activity, as observed in the analysis of about 18 Drosophila core 
promoters (Burke and Kadonaga 1997; Kutach and Kadonaga 2000). All of the known DPE-
containing promoters possess identical spacing between the Inr and DPE motifs, and the alteration 
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of the spacing between the Inr and DPE by a single nucleotide causes a several-fold reduction in 
TFIID binding and basal transcription activity (Burke and Kadonaga 1997; Kutach and Kadonaga 
2000). The consensus sequence for the DPE is estimated to be A/G+28-G-A/T-C/T-G/A/C (Kutach 
and Kadonaga 2000). Although the DPE consensus sequence is somewhat degenerate, it should be 
considered that both DPE and Inr motifs are required in DPE-dependent promoters and that the 
spacing between the DPE and Inr is invariant (which enables the cooperative binding of TFIID to 
the two motifs). Thus, the functional consensus for DPE-dependent core promoters consists of the 
Inr and DPE motifs with the DPE located at +28 to +32 relative to A+1.  
The MTE is a new core promoter element conserved from Drosophila to humans, which promotes 
transcription by RNA polymerase II when it is located precisely at positions +18 +27 relative to A+1 
in the initiator element. The MTE requires the Inr, but functions independently of the TATA-box 
and DPE. Notably, the loss of transcriptional activity upon mutation of a TATA-box or DPE can be 
compensated by the addition of an MTE. In addition, the MTE exhibits strong synergism with the 
TATA-box as well as the DPE (Lim et al. 2004). 
The DCE element firstly found in the human β-globin promoter is present in a large number of 
promoters and with high incidence in promoter containing a TATA motif; it is constituted by three 
sub elements of which one is independent of the others; it is reported to bind solely the TAFs within 
the TFIID complex (Dong-Hoon Lee et al., 2005). 
Promoter elements become non-functional when moved even a short distance from the start of 
transcription or if their orientation is altered.  
Besides the aforementioned core promoter elements, the region immediately upstream (up to a few 
hundred base pairs) from the core promoter is defined proximal promoter and contains primary 
regulatory elements defined as specific transcription factors binding sites. 
These sequences determine whether the promoter is expressed in all cell types or is specifically 
regulated. Promoters that are constitutively expressed (their genes are sometimes called 
housekeeping genes) have upstream sequence elements that are recognized by ubiquitous activators.  
 
 
2.2 Distal regulatory elements 
 
As for distal regulatory sites, enhancers are defined as cis-acting DNA sequences that stimulate 
transcription independently of the sequence orientation or transcriptional start site position (Banerji 
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et al., 1981), indeed they can be found far upstream, downstream or even within the gene. 
However these elements function in ways that go beyond this molecular shorthand. As a matter of 
fact the nucleoprotein complexes on enhancers can constitute the “enhanceosome” in which there’s 
a high degree of cooperativity between enhancer-bound proteins, such that alterations in individual 
binding sites, or the absence of one regulatory protein, can have drastic effects on enhancer output.  
Nevertheless enhanceosome may represent only a subclass of genetic switches and an alternative 
mechanisms, the “billboard enhancer”, could take account for complex patterns of expression during 
development; in this model the entire element need not to function as a cooperative unit, but rather 
as an ensemble of separate elements that independently affect gene expression.  
Enhancer associated proteins can bind in sequence-specific or sequence-non-specific manners, 
indirectly through protein-protein contacts, promoting the decondensation of repressed chromatin 
and facilitating the assembly of the transcription machinery at gene promoters.  
One class of proteins, represented by the SWI/SNF complexes, modifies the chromatin structure 
non-covalently in an ATP-dependent fashion (Kingston et al., 1999). These proteins, once recruited 
to enhancer elements, can reposition specific nucleosomes along the DNA. Consequently core 
promoters may be exposed to allow transcription to start. 
One more regulatory sequence at service of genes to ensure their proper temporal and spatial 
transcription, in the same class as enhancers and promoters, is the insulator. 
Insulators have been characterized by two experimentally defined properties involving altered gene 
expression; the first one is called “enhancer blocking or promoter decoy” and occurs when an 
insulator is positioned between an enhancer and a promoter acting as a barrier against a signal 
propagated from the enhancer, as it interact with enahncer-bound factors and prevents the proper 
interaction of enhancer with its target promoter (Geyer and Clark, 2002). The second property is 
referred as “barrier activity” and occurs when insulators flank a transgene and prevent its 
transcriptional repression from positioning effects of heterocromatin by recruiting  histone 
modifying or gene-activating factors (Capelson et al., 2004). 
In this manner insulators are able to exert two opposing effects on transcription. 
A view of cis- regulatory elements analyzed so far is schematized (Fig. 2)  
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2.3 Mutations in regulatory elements 
 
Cis-regulatory polymorphisms 
 
A recent survey on known functional cis-regulatory variants has revealed a number of distinctive 
characteristics of the model of action of this variants, with implications for their evolution and their 
role in phenotypic variation. 
First, transcription factors typically regulate many downstream target genes whose identities differ 
among individuals on the basis of the variation in cis-regulatory sequences. 
Consequently, changes in expression or structure of a transcription factor, will be highly pleiotropic, 
influencing many downstream loci, but also highly epistatic, dependent on genetic background. 
Second, “epistasis in cis” where the effect on transcritpion of one cis regulatory variant depends on 
covariation at a linked cis regulatory site. 
Third, many of the genes with regulatory polymorphisms interact with one another in regulatory, 
metabolic and physiological networks. As a consequence, moderate levels of variation at any one 
locus will be amplified by the numer of genes in the network to yield high levels of polymorphism 
at the network level.  (Rockman and Wray, 2002). 
 
 
Fig.2: Different classes of cis-regulatory elements in a typical human genome. Transcription initiates at 
promoters (blue DNA), which are further activated by enhancers (green DNA) or repressed by silencers (red DNA). 
The activity of enhancers and silencers may be confined by insulators (yellow DNA), which also prevent the 
spreading of repressive condensed chromatin structures (shown at each end of this chromosomal region). This model 
depicts 
nucleosomes as DNA (gray helix) wound around histone proteins (various colors), which are less dense at exposed 
DNA regulatory elements when bound by various transcription factors (blue ovals), activator and repressor proteins 
(green and red ovals, respectively), and CCCTC-binding factor (yellow oval) (Heintzman and Ren, 2009). 
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Cis-regulatory elements mutations 
 
Mutations in transcriptional regulatory elements have been found associated with numerous human 
disease (Table1). In some cases the defect is known, as in the Bernard-Soulier Syndrome where 
mutatons in GpIbβ gene proximal promoter result in reduced GATA-1 binding and GpIbβ gene 
expression. In other cases the underlying defect is less well defined. For instance, a 12-mer repeat 
expansion in the promoter of cystatin B gene has been proposed to cause progressive myoclonus 
epilepsy, presumably by altering the spacing of element in the promoter. 
A variety of cancers result from chromosomal rearrangements involving either regulatory elements 
or transcription factors. For example, promoter and/or enhancer elements of one gene may become 
aberrantly linked to a proto-oncogene, thereby causing altered expression of an oncogenic protein. 
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CHAPTER 2 
 
Transcriptional regulation of thyroid development in mouse 
 
2.1 Thyroid gland development 
 
The thyroid gland in mammals is located in the neck region. The gland produces thyroid hormones 
and calcitonin in two distinct cell types, the thyroid follicular cells (TCFs) and the parafollicular or 
C cells, respectively; all mammals share the same endocrine cell types and histoarchitecture.  
The TFCs, the most numerous cell populations in the gland, form the thyroid follicles which serves 
as storage and release of the thyroid hormone thyroglobulin (Tg). 
Moreover these cells are highly polarized, with thyroperoxidase (TPO) on the apical membrane, and 
TSH receptor and the sodium/iodide symporter (NIS) on the basolateral membrane. 
The expression of all these genes represents the characteristic phenotype of a terminally 
differentiated thyroid cell. 
The C cells, scattered in the interfollicular space, produce calcitonin, an hormone implicated in 
calcium homeostasis. 
The thyroid gland originates from the ventral floor of the foregut first as a thickening, the thyroid 
anlage at E8.5; then this thickening proliferates, deepens and invades the surrounding mesenchyme 
forming a small pit, the thyroid bud (E9), which then becomes an outpouching of the endoderm, 
adjacent to the distal part of the outflow tract of the developing heart. 
By E10 the thyroid primordium resembles a narrow neck that rapidly becomes a diverticulum. 
The expansion of the thyroid primordium correspond to the lost of connections with the floor of 
pharnynx, the thyroglossal duct which connects the remnant of anlage with the thyroid primordium, 
in fact, disappears. 
By E15-E16 the thyroid lobes expand considerably and the gland exhibits its definitive shape: two 
lobes connected by a narrow isthmus. 
The onset of folliculogenesis is evident at E15.5 as well as the detection of calcitonin producing C 
cells derived from the fusion of ultimobranchial bodies with the primitive thyroid at E14. 
The completion of organogenesis is in the functional differentiation of thyroid follicular cells that 
express a series of proteins, mentioned above, that are typical of TFCs and that are essential for 
thyroid hormone biosynthesis. Genes typical of this stage appear according to a given temporal 
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pattern: Tg, TPO and TSH receptor genes are expressed by E14.5; sodium iodide symporter (NIS) is 
detected by E16. T4 is first detected at E16.5. The differentiative program of TFCs is completed 
only when the gland reaches its final location; this point raises the question of whether a time or 
space-dependent signal is responsible for it. The last hypothesis is rejected by observations that 
patients with sublingual thyroid do produce in low amounts thyroid hormones. 
The precise timing in the start of gene expression program necessary for thyroid hormone 
biosynthesis indicates that an ordered genetic mechanism must be responsible for it. 
 
 
2.2 Thyroid transcription factors and their role in development  
 
At the thyroid anlage stage (specification stage) thyroid cells express a specific combination of 
transcription factors: Titf1/Nkx2-1 (thyroid transcription factor-1), Hhex (hematopoietically 
expressed homeobox), Pax8 (paired box gene 8) and TTF-2/Foxe1 (thyroid transcription factor-2). 
The combination of these proteins is a unique feature of thyroid precursors cells and their 
descendants as fully differentiated thyroid follicular cells producing thyroid hormones. 
All of these transcription factors are indispensable for normal thyroid, whose morphogenesis is 
severely impaired in their absence. 
Titf1 is a homeodomain-containing transcription factor, firstly identified as a thyroid-specific DNA 
binding factor recognizing thyroglobulin and thyroperoxidase promoters; it belongs to the Nkx2 
family of transcription factors, since it is named also Nkx2-1. 
Since the expression in thyroid anlage in primitive pharynx, Titf1 remains expressed in thyroid 
follicular cells during all stages of development and in adulthood, being responsible of 
organogenesis and of the expression of TFC specific genes in adult life. 
The thyroid primordium in Titf1/Nkx2-1 -/- embryos is in correct position but then undergoes 
degeneration at E10.5 and eventually disappears by E11. 
These data, together with the presence of apoptotic cells, suggest that Titf1/Nkx2-1 is required to 
prevent the initiation of an apoptotic process, being essential for the survival of thyroid cell 
precursors but not for their initial formation. 
This gene is also expressed in the trachea, lung epithelium and some areas of the forebrain including 
developing posterior pituitary; its expression in adulthood remains unvaried in lung epithelium and 
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posterior pituitary, while in the brain it becomes restricted to the paraventricular regions and some 
hypothalamic nuclei.  
Titf1 regulates different genes in different cell types; for example the bone morphogenetic protein 
(Bmp)4, expressed in the growing tip of the branching lung epithelium in a normal embryo, is 
undetectable in the lung of Titf1/Nkx2-1 -/- embryos, while in the developing posterior pituitary 
which express Bmp4 and fibroblast growth factor (Fgf)8 in normal conditions, the lack of Titf1 
influences only Fgf8 expression, leading to apoptosis in the anterior pituitary bud and later on in the 
posterior bud as well. 
There’s a sharing of Titf1 regulated mechanisms between the thyroid and pituitary cells that in both 
are required for the survival of cells. 
Hhex is a homeodomain containing transcription factor first identified in hematopoietic cells 
(Crompton et al., 1992), characterized by a N-terminal prolin-rich region, involved in regulating the 
transcription of the target genes. 
The homeobox gene Hhex is expressed in the anterior visceral endoderm (AVE) and definitive 
endoderm of the early mouse embryo, two tissues implicated in patterning the anterior neural plate. 
In particular AVE is derived from a handful of proliferating cells in the distal visceral endoderm, 
which alone express Hhex. 
Moreover graft experiments in the mouse demonstrates that the AVE, the node and its derivative, 
the axial mesendoderm, cooperate in the induction and patterning of the brain, while a complete 
neural axis is to be induced by a combination of the AVE, anterior epiblast and the early node. 
Later in embryo development Hhex is localized in the ventral gut and then marks the primordium of 
several organs derived from the foregut such as thyroid, liver, thymus, pancreas and lungs. 
In Hhex null embryos at E9 the thyroid anlage is present and comparable with the wild type and the 
expression of the other thyroid markers Titf1, Pax8 and Foxe1 is not affected. 
Thus, specification of the thyroid cells does not require Hhex. 
At E10 in mutant embryos the thyroid bud is impaired with alterations in the number of thyroid cell 
precursors and in its morphology, the expression of Pax8 and Foxe1 proteins is strongly reduced, 
while the expression of Titf1 protein is not significantly reduced at this stage. 
A probably role of Hhex could be the maintenance of Titf1, Pax8 and Foxe1 expression in the 
developing thyroid. 
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Foxe1/TTF-2 is a member of winged helix/forkhead family of transcription factors first identified as 
a thyroid specific nuclear protein recognizing specific DNA sequence on both thyroglobulin and 
thyroperoxidase promoters under hormone stimulation. 
Foxe1 mRNA is detected at E8.5 in all the endodermal cells of the floor of the foregut, including the 
thyroid anlage; hence at variance with Titf1/Nkx2-1 and Pax8, whose expression is limited to the 
thyroid anlage, Foxe1has a wider domain of expression. 
In ectoderm derived structures beyond the posterior stomatodeum and buccopharyngeal membrane, 
TTF-2 is localized to Rathke’s pouch, an ectodermal diverticulum in the roof of the primitive oral 
cavity that forms adenohypophysis, but not in the neuroectodermal derivatives that give rise to 
neurohypophysis; it is not expressed in later stages over E11.5 in this gland. TTF-2 is also 
expressed in two other ectoderm derivatives:  nasal choanae (the openings of the olfactory pits into 
the oropharyngeal cavity), whiskers and hair follicles. 
TTF-2 is expressed in the epithelial layer of the foregut lining the pharyngeal arches and in their 
derivative tissues thyroid, tongue, epiglottis, palate, and oesophagus, it is absent in the 
thymus,parathyroid, and ultimobranchial body, which are derivatives of the pharyngeal pouches free 
of TTF-2. 
Expression of TTF-2 in thyroid cell precursors is maintained during development and persists in 
adult thyroid follicular cells. 
Homozygous foxe1 -/- mice die within 48h, they display no thyroid in its normal location and the 
absence of thyroid hormones. 
Despite the fact that the thyroid budding primordium is normal, at E9.5 thyroid precursor cells are 
still on the floor of pharynx, while in wild type embryos they are detached from the pharynx cavity 
and begin to descend. Mutant mice later in development could either exhibit no thyroid gland at all or 
a small thyroid remnant attached to the pharyngeal floor in which cells complete their  differentiative 
process. 
Pax8 is a member of a family of transcription factors characterized by a conserved DNA binding 
domain of 128-amino acids, the paired box, identified in the Drosophila segmentation genes paired 
(Kilchherr et al., 1986; Frigerio et al., 1986). 
Like Titf1/Nkx2-1, Pax8 is detected in the developing thyroid from E8.5 at the time of specification 
and its expression is maintained in thyroid follicular cells during all stages of development. 
15 
 
In the nervous system Pax8 mRNA is transiently expressed in the myelencephalon and through the 
entire length of the neural tube; at later stages of the development as well as in adulthood there are 
no more signals in the brain. 
Pax8 mRNA is expressed in all stages of mammalian kidney development: from pronephric duct 
precursors that originates from nephrogenic mesenchyme to the metanephros, which originates from 
reciprocal inductive interactions between the ureteric bud and the metanephric mesenchyme; Pax8 
persist in adult kidney. In particular Pax8/Pax2 coexpression in kidney shows redundant gene 
functions: the double mutant, unlike the single mutants, shows no early intermediate mesenchyme 
commitment to nephric duct lineage (Dahl et al., 1997). 
Pax8 -/- homozygous mice born at the expected Mendelian frequency but show growth retardation 
and die within 2-3 weeks. These mice do not display any apparent defects in the spinal cord, 
midbrain/hindbrain boundary or kidneys; on the contrary the thyroid gland is severely affected: the 
thyroid diverticulum is able to evaginate from the endoderm but Pax8 is required for further 
development, as neither follicles nor TFCs can be detected and the rudimentary gland is composed 
almost completely of calcitonin-producing C cells. Hypothyroidism is the cause of death of the 
mutated  animals: the administration of T4 allows the animals to survive. 
Thus, like Titf1/Nkx2-1, Pax8 seems to be required for the survival of thyroid cell precursors and 
not for their specification.  
 
 
2.3 Role of Pax8 in thyroid differentiation 
 
Besides the just mentioned role in morphogenesis of the TFC component of the thyroid gland, there 
are at least two more evidence that point out Pax8 as a “master gene” for the regulation of the 
thyroid differentiated phenotype.  
The first evidence has been obtained by using the sperimental model of the thyroid cell in colture. 
The Polyoma antigen T transformed PCPy cell line, derivative of the differentiated thyroid cell line 
PC Cl3, loses the thyroid-differentiated phenotype both as tissue specific gene expression of Tg, 
TPO, NIS, and as TSH dependence for proliferation.  
Among the thyroid-specific transcription factors discussed so far, only the expression of Pax8 is 
severely reduced. 
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The reintroduction of the gene in PCPy cells is sufficient to activate expression of the endogenous 
genes encoding Tg, TPO and NIS and suggest a fundamental role of this transcription factor in the 
maintenance of functional differentiation in thyroid cells (Pasca di Magliano et al. 2000). 
The second line of evidence derives from patients suffering from congenital hypothyroidism, the 
most frequent endocrine disorder in newborn (Klett M. 1997), characterized by elevated levels of 
TSH in response to reduced thyroid hormone levels. In most cases congenital hypothyoridism is due 
to thyroid disgenesis, ie disturbance in the gland’s organogenesis, which result in thyroid agenesis, 
ipoplasia or ectopia. 
The involvement of Pax8 in thyroid dysgenesis is demonstrated by the fact that all affected 
individuals are heterozygous for loss-of-function mutations in its DNA binding domain and, in the 
familial cases, transmission is autosomal dominant.  
Hence the importance of the role covered by Pax8 in the complex molecular mechanism of thyroid 
differentiation, though, in thyroid disgenesis, incomplete penetrance takes account of severe, mild, 
up to no phenotype, in patients carrying Pax8 inactivating mutations (Congdon T. 2001). 
 
 
2.4 Identification of Pax8 thyroid specific far upstream element and proximal promoter 
 
Comparative studies on human and mouse genomic sequences flanking the Pax8 gene revealed for 
conserved non coding sequences (CNS) instrumental in guiding the thyroid specific expression of 
Pax8: CNS 87 and CNS 14. 
The CNS 87 (conserved non coding sequence 87) has all the features typical of an enhancer, being 
located 87 kb upstream the transcriptional start site and stimulating transcription of a reporter gene 
in a very strong and thyroid specific manner. 
In particular Dnase-I footprinting analysis of CNS 87 revealed only six protected regions 
(denominated FT), which, incubated, with either thyroid (PC Cl3) or non-thyroid (HeLa) protein 
extracts gave different band retardation pattern in EMSA assay. 
Among them, bioinformatic tools predicted FT-1 and FT-6 to have binding sites for the thyroid 
enriched transcription factor TTF-1, element subsequently confirmed by EMSA assay. 
Taken together these data indicates that CNS87 is a distant regulatory element that controls Pax8 
expression through TTF-1 binding on the sequence (Nitsch et al., 2010). 
17 
 
CNS 14 (conserved non coding sequence 14) spans from nucleotides -369 to + 680 (relative to 
transcriptional start site) and directs thyroid specific transcriptional activity, features proper of a 
promoter; in particular this activity is retained by the subregion 14.2 (-369 +100) thus identified as 
the Pax8 proximal promoter. Exhaustive analysis of the entire sequence, by EMSA assays on small 
19 nucleotides sequences, has led to the observation of different DNA complexes, both thyroid and 
non-thyroid specific (Fig. 3). 
 
 
 
 
The thyroid specific regulatory elements named as C4 and A7, from the initial nucleotide 
subdivision, have been further analyzed. 
In the C4 sequence there’s a Pax8 consensus strongly conserved in thyroglobulin and 
tireoperoxidase promoters; this datum has been confirmed by the purified, bacterially produced 
Pax8 paired domain (bPD-PAX8) binding complex onto the C4 oligonucleotide and by the Pax8-
FLAG fusion protein, expressed in HeLa cells, giving the same band retardation in EMSA assays. 
As for A7 sequence no binding was validated upon prediction of the bioinformatic tools 
(TRANSFAC-Genomatix) of the thyroid specific factors Nkx2-1, Foxe1, Pax8 and Hhex. 
This sequence recognizes a novel thyroid specific DNA binding protein not characterized yet (Di 
Gennaro et al., 2012). 
 
 
 
 
Fig.3:  Architecture of mouse Pax8 promoter 
The sequence of the mouse Pax8 promoter (M) is 
shown, aligned with the human sequence (H). 
Dashes indicate spacing introduced to maximize the 
alignement between the two sequences. In the 
human sequence, only the nucleotide changes with 
the mouse sequence are reported. Squares indicate 
binding factors above the corresponding recognition 
sequence (Di Gennaro et al., 2012) 
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RESULTS 
 
 
Previous studies on the Pax8 promoter reveal a novel thyroid-specific DNA binding 
activity.  
 
The Pax8 minimal promoter has been recently described (Di Gennaro et al., 2012) as the 
CNS-14.2 (conserved sequence) region spanning the positions -369 to +1 relative to the gene 
transcriptional start site and expressed specifically in thyroid cells. The entire promoter was 
subdivided in several oligos and each was challenged with nuclear extracts derived from 
FRTL-5 and HeLa cells to detect thyroid-specific DNA binding activity. I studied the binding 
to one of these oligonucleotides that was proved to recognize a thyroid specific transcription 
factor; from now on I will refer to this sequence as A7 (Fig. 4 A,B).  
A first attempt aimed at identifying the activity capable of binding to the A7 sequence, 
included the purification of the proteins involved and their identification by mass spectrometry 
(Di Gennaro, unpublished). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4A: Thyroid specific transcription factor 
bind to the A7 sequence 
Radio-labeled A7 was incubated with nuclear 
extracts from different cell lines. Radio labeled 
Sp1 oligonucleotide was used as control to 
monitor the quality of the nuclear extracts used. 
Line 1 and 7, free probe; line 2 and 8, FRTL-5 
nuclear extract; line 3 and 9, HeLa nuclear 
extract; line 4 and 10, MDCK nuclear extract; 
line 5 and 11, SK-N-BE nuclear extract; line 6 
and 11, ES nuclear extract. 
4B: Position of A7 sequence within the 14.2 
promoter 
 
1 2 3 4 5 6 7 8 9 10 11 12 
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Several proteins were identified, among these I tested whether Gtf2i could be the protein 
involved in binding to A7. 
I first tested whether Gtf2i is involved in the regulation of the Pax8 promoter. 
 
 
Expression of Pax8 mRNA in FRTL-5 is not inhibited by Gtf2i downregulation 
 
To prove the involvement of Gtf2i on Pax8 transcriptional regulation, I performed the 
silencing of the protein in FRTL-5 cell line by RNA interference and look at the effect on 
Pax8 transcription. 
An effective reduction in the levels of Gtf2i protein was confirmed by western blot analysis, 
using an anti-Gtf2i antibody (Fig. 5).  
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative real time RT-PCR experiment was then performed to quantify Pax8 mRNA 
expression level in Gtf2i partially depleted samples. 
Fig.5: Downregulation of Gtf2i expression in FRTL-5  
Western Blot analysis of Gtf2i  protein expression 96 h after RNA 
interference transfection; panel A, Gtf2i expression; panel B, 
Tubulin expression.  
Line 1, non transfected (NT); line 2, scramble 50 nM; line 3, empty 
well; line 4, 50 nM RNAi targeting Gtf2i rattus mRNA sequence. 
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Pax8 mRNA level in FRTL-5 cell line was found to be 1,25 fold less compared to the 
scramble (Fig. 6). 
This mild reduction could be due to low Gtf2i protein levels still able to regulate the promoter 
or to the Pax8 autoregulation of its own promoter as previously demonstrated (Di Gennaro et 
al. Thyroid 2012). 
Hence the need to develop a new experimental system able to confirm the data obtained by 
mass spectrometry. 
 
 
 
 
Immunodepletion-EMSA does not confirm Gtf2i involvement in A7 transcriptional 
regulation. 
 
To further test the involvement of Gtf2i involvement in the binding to the A7 sequence, I set 
up an immunodepletion assay for removing this protein from the extracts. 
Briefly total protein extracts were submitted to immunoprecipitation with the specific antibody 
and the antigen-antibody complexes were isolated by protein A agarose beads. 
The same procedure was simultaneously repeated with an unspecific antibody taken as a 
control. 
Immunocomplexes and supernatants were both tested by western blotting.  
Fig.6: The down regulation of Gtf2i gene expression by RNAi  
does not decrease significantly Pax8 transcript expression. 
Pax8 transcript abundance was measured by qRT-PCR as fold of 
induction on scramble.    
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Immunodepletion with the specific antibody removes efficiently Gtf2i from the extract, as all 
the protein is efficiently immunoprecipitated and no more visible in supernatant, while the 
control has just the opposite trend (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The residual activity on A7 after Gtf2i depletion was tested by EMSA assay (Fig. 8). 
As shown the complex with the A7 oligonucleotide is not affected by Gtf2i depletion from the 
protein mixture, in fact comparing αGtf2i supernatant with αFLAG supernatant the complex 
have roughly the same trend. 
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1 2 3 4 5 6 7 8 9 
GTF2I 
TUBULIN 
Fig.7: Immunodepletion of Gtf2i in FRTL-5 cells 
Lane 1, input total FRTL-5 extract; lane 2-4, immunoprecipitation 
of Gtf2i: immunocomplexes eluted in denaturing condition with 
litium dodecyl sulfate (LDS) (2), or in non denaturing glicine 
elution (3-4); lane 6, supernatant immunodepleted of Gtf2i; lane 6-
8, control immunoprecipitation with αFLAG antibody: 
immunocomplexes eluted in LDS denaturing conditions (7) and in 
non denaturing glicine elution (7-8); lane 9, supernatant of αFLAG 
immunoprecipitation 
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Moreover, as a further confirmation, anti Gtf2i antibody was incubated in the binding mix 
with FRTL-5 extract and A7 probe, to detect a possible supershift as evidence of Gtf2i binding 
onto the sequence. 
The absence of a supershift is consistent with the immunodepletion experiment and thus 
support the notion that Gtf2i is not the protein responsible for binding to A7 detected in 
thyroid cells extracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.8: EMSA assay to test the binding 
activity of FRTL-5 extract 
immunodepleted of GTf2i. 
Lines 1-5 binding assay on A7 probe; line 1, 
free probe; line 2, FRTL-5 input total extract; 
line 3, Gtf2i-immunodepleted FRTL-5 
extract; line 4, supernatant of control αFLAG 
immunoprecipitation; FRTL-5 extract 
incubated with αGtf2i in the binding assay; 
Lines 6-9 binding assay on Sp1 probe; line 6 
free probe, line 7, FRTL-5 input total extract; 
line 8, Gtf2i-immunodepleted FRTL-5 
extract; line 9, supernatant of control αFLAG 
immunoprecipitation. 
 
1 2 3 4 5 6 7 8 9 
 
A7 SP1 
 
FRTL-5 - + - - + - + - - 
Supernatant IP GTF2I - - + - - - - + - 
Supernatant IP FLAG - - - + - - - - + 
Anti GTF2I - - - - + - - - - 
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A bioinformatic approach identifies one factor that recognizes a consensus on A7 
sequence 
 
In order to identify other candidates the sequence A7 was analyzed by MatInspector 
Professional program, which retrieved a binding consensus for the transcriptional factor 
NFAT5 (Fig. 9). 
Interestingly this sequence is part of the core recognized by the NFAT family of transcription 
factors (Table 1) to which NFAT5 belongs. 
 
 
 
 
 
 
Since NFAT5 was shown to be expressed in Jurkat cells, we tested an antibody directed 
against NFAT5 on extracts of this cell line. As reported the antibody recognizes a band of 
about 170 kDa (Fig. 10). I then used the same antibody on FRTL-5 and HeLa extracts: as 
shown NFAT5 is present in both cell lines with the same pattern of protein expression 
observed in Jurkat. 
 
 
NFAT family members Alternative names mouse chromosome location human chromosome location 
        
NFATc1 NFAT2 and NFATc Chr18:80606205-80713071 bp Chr18:77155772-77289323 bp 
NFATc2 NFAT1 and NFATp Chr2:168476410-168601657 bp Chr20:50007765-50179168 bp 
NFATc3 NFAT4 and NFATx Chr8:106059603-106130537 bp Chr16:68119375-68260837 bp 
NFATc4 NFAT3 Chr14:55824795-55833943 bp Chr14:24836145-24848810 bp 
NFAT5 TonEBP and OREBP Chr8:107293470-107379517 bp Chr16:69598997-69738553 bp 
 
 
 
 
 
 
 
             gcgatccaagagtTTCCagagaac  
              
Fig.9:  NFAT5 consensus binding motif 
found on A7 sequence. 
Table 1:  NFAT family of transcription factors 
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To test if NFAT5 binds A7 I decided first to demonstrate whether extracts of Jurkat cells 
contain an activity that recognizes this oligo. As a control for the quality of Jurkat extracts we 
used an oligo derived from tumor necrosis factor α promoter that is known to be also regulated 
by NFAT5 (I’ll refer to this sequence as NFAT5RecognitionSite). 
As shown (Fig. 11) by the protein complex bound to the NFAT5RS, the quality of Jurkat 
extracts is good, in addition in this extracts there is also an activity that binds A7. 
Conversely I tested whether proteins from FRTL-5 recognize the NFAT5RS or HeLa extracts 
taking as control the A7 sequence (Fig. 12). 
Since the NFAT5RS is recognized by FRTL-5 and not by Hela, I conclude that the activity 
binding to this oligo is common to FRTL-5 and Jurkat and absent in HeLa cells. However in 
both experiments there is not supeshift probably due to the well-known fact that antibodies in 
supershift assays don’t have assurance of working. 
These binding experiments, together with western blot, can’t definitely state NFAT5 
uninvolvement in activity on A7, as it could be negatively regulated in HeLa.   
Fig.10:  NFAT5 expression in Jurkat, FRTL-5 and HeLa cells 
NFAT5 is expressed one band of about 170kDa in all cell lines 
Line 1, Jurkat total extract; line 2, FRTL-5 total extract; line 3 HeLa total 
extract. 
Tubulin was hybridized onto the same filter to test the quality of the 
extract and the relative distribution in the three cell lines. 
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In addition these data cannot either exclude the eventual binding of other members of the 
NFAT family that share a highly conserved DNA-binding domain conferring common DNA-
binding specificities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: Gel Shift of Jurkat extract incubated with NFAT5RS and 
A7 sequences. 
(A) Jurkat nuclear protein extract was incubated, alone or together, with 
an antibody anti-NFAT5, in EMSA assays with radiolabeled A7 and 
NFAT5RS probes. Line 1, A7 free probe; line 2, Jurkat nuclear extract; 
line 3, supershift analysis with NFAT5 antibody; line 4, supershift 
control analysis with HA antibody; line 5, NFAT5RS free probe; line 6, 
Jurkat nuclear extract; line 7, supershift analysis with NFAT5 antibody; 
line 7, supershift control analysis with HA antibody;  
 
JURKAT - + + + 
Anti NFAT5 - - + - 
Anti HA, control - - - + 
 
- + + + 
- - + - 
- - - + 
 1 2 3 4 5 6 7 8 
A7 NFAT5RS 
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Immunodepletion proves that NFAT5 is not involved in binding to A7. 
 
As for the transcription factor Gtf2i, even in this case, we sought confirmation for NFAT5 
bound on A7 by immundepletion-EMSA assay in FRTL5 total extracts. 
Briefly a first round of immunoprecipitation, which included the interaction with the only 
antibody, was followed by the separation of immunocomplexes from the lysate by the addition 
of protein A agarose beads.  
Fig.12:  Gel Shift of FRTL-5 and HeLa extracts incubated with NFATRS and A7 
sequences. 
FRTL-5 nuclear protein extract was incubated, alone or together, with an antibody 
anti-NFAT5 in EMSA assays with radiolabeled NFAT5RS and A7 probes; HeLa 
nuclear cell lysate as binding negative control incubated with NFAT5RS and A7 
radio-labeled probes. 
Line 1, NFAT5RS free probe; line 2, FRTL-5 nuclear extract; line 3, supershift 
analysis with NFAT5 antibody; line 4, supershift control anlysis with anti HA 
antibody; line 5, HeLa nuclear extract; line 6, A7 free probe; line 7, FRTL-5 nuclear 
extract; line 8, supershift analysis with NFAT5 antibody; line 9, supershift control 
analysis with HA antibody; line 10, HeLa nuclear extract. 
 
- + + + - 
- - - - + 
- - + - - 
- - - + - 
 
 
FRTL-5 - + + + - 
HeLa - - - - + 
Anti NFAT-5 - - + - - 
Anti HA, control - - - + - 
 
1 2 3 4 5 6 7 8 9 10 
A7 NFAT5RS 
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As procedural control it was performed a simultaneous immunoprecipitation with an unrelated 
antibody.  
The band at 150 kDa recognized by our antibody was efficiently depleted from total protein 
mixture (Fig. 13). 
 
 
       
 
 
 
 
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13:  Immunodepletion of NFAT5 in FRTL5 cells 
FRTL-5 total extracts (1) were challenged with anti NFAT5 antibody (2-5) and with anti FLAG control 
antibody (6-9). 
The 150 kDa protein is visibile in denaturing elution of immuno-complexes (2) and mildly visibile in non 
denaturing glicine elution (3-4), the full depletion is visible as no band at 150 kDa in anti NFAT5 
supernatant (5).  
Denaturing elution of control anti-FLAG immunoprecipitation shows no detectable band on western (6) as 
well as in non denaturing glicine elution of anti FLAG immunocomplexes (7-8); anti FLAG supernatant 
show the band (9) as expected. 
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The depleted extracts were then tested for binding activity on A7 sequence by EMSA assay 
(Fig. 14). 
As shown the binding complex is not affected by the lack of the NFAT5 protein, both the 
αNFAT5 and αFLAG depleted lysates show activity on A7. 
We can conclude that NFAT5 is not the candidate protein in binding A7. 
 
 
 
 
 
Fig.14: FRTL-5 extract immunodepleted  
of NFAT5 still bound to the A7 sequence. 
Line 1, free probe; line 2, FRTL-5 nuclear 
extract; line 3, supernatant of αNFAT5 
immunoprecipitation; line 3, supernatant of 
control αFLAG immunoprecipitation. 
 
 
FRTL5 - + - - 
Supernatant 
IP NFAT5 
- - + - 
Supernatant 
IP FLAG 
- - - + 
 
1 2 3 4 
A7 
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Purification of transcription factor(s) binding to the A7 promoter region 
 
As we did not get any result in the identification of the transcriptional activity on Pax8 
promoter so far, we attempted its purification once again from FRTL-5 cells. The only 
difference between the previous procedure (Di Gennaro, unpublished data) was the use of the 
blue sepharose chromatography in place of the heparin in one of the purification steps. 
As described in the Materials and method section 90 mg of nuclear extracts were loaded onto 
DEAE chromatography at a molar KCl concentration useful to prevent the binding from the 
resin itself, the flow through extract was then purified by Blue Sepharose chromatography.  
Elution of discrete fractions was obtained by increasing salt concentration and the result was 
analyzed by EMSA (Fig. 15) 
 
 
 
                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15: EMSA of fractions eluted from Blue 
sepharose chromatography, binding on A7 
sequence. 
Lane 1, free probe; lane 2 FRTL-5 nuclear  
extract; lane 3, input Blue sepharose; lane 4, 
flow through (FT) Blue Sepharose; lane 5-11, 
fractions (Fr.) of Blue sepharose eluted with a 
linear KCl gradient from 0.3 to 1.2M 
 
 
FRTL-5 - + - - - - - - - - - 
Input - - + - - - - - - - - 
FT - - - + - - - - - - - 
Fr. 0.3 - - - - + - - - - - - 
Fr. 0.5 - - - - - + - - - - - 
Fr. 0.6 - - - - - - + - - - - 
Fr. 0.7 - - - - - - - + - - - 
Fr. 0.8 - - - - - - - - + - - 
Fr. 1 - - - - - - - - - + - 
Fr. 1.2 - - - - - - - - - - + 
1 2 3 4 5 6 7 8 9 10 11 
 
A7 
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As shown the active complex spans on different elutions but focuses mainly on higher saline  
concentrations. 
This is why we then decide to proceed to the next purification step by pulling active fractions 
from 0.6 to 1.2M KCl and bringing them to lower salt concentrations to allow the binding to 
the DNA affinity column, made up of purified A7 oligonucleotide multimers coupled to a 
CNBr activated resin. 
Retained proteins were eluted by increasing KCl concentration and fractions thus obtained 
were analyzed by EMSA assay. 
The majority of the binding activity is retained by the 0.4M fraction, with a smaller proportion 
in the 0,3M fraction as well (Fig. 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.16: EMSA of fractions eluted from 
A7/DNA affinity chromatography, binding 
on A7 sequence. 
Lane 1, free probe; lane 2 FRTL-5 nuclear 
extract; lane 3, input DNA affinity; lane 4, 
flow through (FT) DNA affinity; lane 5-12, 
fractions of DNA affinity eluted with a lineat 
KCl gradient from 0.15 to 1.5M KCl 
 
 
FRTL-5 - + - - - - - - - - - - 
Input - - + - - - - - - - - - 
FT - - - + - - - - - - - - 
Fr. 015 - - - - + - - - - - - - 
Fr. 0.2 - - - - - + - - - - - - 
Fr. 0.3 - - - - - - + - - - - - 
Fr. 0.4 - - - - - - - + - - - - 
Fr. 0.5 - - - - - - - - + - - - 
Fr. 0.7 - - - - - - - - - + - - 
Fr. 1 - - - - - - - - - - + - 
Fr. 1.5 - - - - - - - - - - - + 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A7 
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All the fractions were TCA precipitated, resolved by SDS PAGE and colloidal Comassie 
stained (Fig. 17).  
 
 
 
 
 
 
 
 
There has been an enrichment in discrete bands of the proteins stained in the active fractions 
0.3-0.4 compared to the non active fractions 0.2-0.15 and to the FT (Fig.17).  
Lines corresponding to 0.2-0.3.0.4M fractions eluted, were excised, divided into bands (Fig. 
18) and subjected to sequence analysis by Mass Spectrometry, at the ISPAAM CNR of 
Naples, Dott. Scaloni laboratory. 
 
 
Fig.17:  SDS PAGE of DNA affinity fractions, stained by Colloidal 
Comassie 
Line 1, flow-throug; lanes 2 to 9, fractions from DNA-affinity 
chromatography eluted with a linear KCl gradient from 0.15 to 1.5M. 
Line 10, size markers. 
 
 
1 2 3 4 5 6 7 8 9 10 
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The analysis output returned a large number of proteins. 
Two bioinformatic approaches were used to highlight the most significant candidates among 
those identified by mass spec. 
The first one consisted in identify proteins from the active fractions absent in the HeLa 
proteome. The second approach consisted in rearrange the data in order to highlight only the 
DNA binding proteins and transcription factors in the active fractions and, among these, were 
taken into consideration those with the greatest number of peptides. 
Different candidates match the above criteria and in particular we focused on three of these: 
NFATc1 meets the first point being found absent in the HeLa proteome (Table 2). 
NFATc2 and NFATc3 meet the second one being the transcription factors most represented by 
the total number of peptides in active fractions (Table 3). 
 
 
Fig.18:  SDS PAGE of DNA affinity fractions, subdivision of the lanes 
analyzed. 
The lines indicate the slices in which every lane has been subdivided; the 
arrows indicate a further subdivision according to the major bands visible 
onto the gel. 
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Uniprot AccNum Protein symbol Gene symbol Description Active fraction Peptides DNA binding domain Transcription factor GO Molecular Function
D4A8C8 GCFC1 GCFC1 GC-rich sequence DNA-binding factor 1 0,4M 2 YES YES transcription factor activity
Q3SWT1 NABP2 NABP2 nucleic acid binding protein 2 0,4-0,3M 9 YES NO DNA repair
D3ZE20 RGD1560225 NFATC1 nuclear factor of activated T-cells 0,4M 2 YES YES transcription factor activity
D3ZZQ2 NFATC2 NFATC2 Protein Nfatc2 0,4-0,3M 179 YES YES transcription factor activity
D3ZU59 NFATC3 NFATC3 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 30,4-0,3M 82 YES YES transcription factor activity
G3V740 NKX2-1 NKX2-1 NK2 homeobox 1 0,4-0,3M 15 YES YES transcription factor activity
P02768 ALB ALB albumin 0,4M 28 NO NO ion, drug, fatty acid binding
D4ACW8 APLF APLF aprataxin and PNKP like factor 0,4M 2 NO NO DNA repair
D3ZEJ9 RGD1310429 C17orf75 chromosome 17 open reading frame 75 0,4M 2 NO NO
D3ZR08 RCG_26646 LOC100362121 Protein LOC100362121 0,4-0,3M 16 NO NO ubiquitin protein-ligase activity
B2RYT0 MRPS21 MRPS21 mitochondrial ribosomal protein S21 0,4-0,3M 5 NO NO ribosomal protein
B2RZD5 RPL22L1 RPL22L1 ribosomal protein L22-like 1 0,4M 2 NO NO ribosomal protein
F1SW39 SBP75 SBP75 PC4 and SFRS1 interacting protein 1 0,4M 2 NO NO
G3V9I9 SREK1 SREK1 splicing regulatory glutamine/lysine-rich protein 1 0,4M 11 NO NO nucleotide binding
Q4KLK1 SRSF11 SRSF11 serine/arginine-rich splicing factor 11 0,4M 3 NO NO nucleotide binding
G3V798 SRSF4 SRSF4 serine/arginine-rich splicing factor 4 0,4M 12 NO NO nucleotide binding
Q68FR8 TUBA3a TUBA3A Tubulin alpha-3 chain 0,4M 2 NO NO structural molecule activity, GTPase activity
G3V7C6 TUBB4b TUBB4B Tubulin alpha-3 chain 0,4-0,3M 26 NO NO structural molecule activity, GTPase activity
Table 2: List of proteins from the active fractions 0.3M-0.4M not found in the HeLa proteome 
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Slice Accession Description Score calc. pI biological actvity Total Peptides
0.3M 4 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]142,84 6,61 transcr. Factor 179
0.3M 5 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]188,09 6,61 transcr. Factor 179
0.3M 6 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]72,85 6,61 transcr. Factor 179
0.3M 7 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]118,28 6,61 transcr. Factor 179
0.3M A D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]189,92 6,61 transcr. Factor 179
0.3M B D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]130,90 6,61 transcr. Factor 179
0.4M 1 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]112,94 6,61 transcr. Factor 179
0.4M 2 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]283,06 6,61 transcr. Factor 179
0.4M 3 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]1052,26 6,61 transcr. Factor 179
0.4M 4 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]711,39 6,61 transcr. Factor 179
0.4M 5 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]311,37 6,61 transcr. Factor 179
0.4M 6 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]340,80 6,61 transcr. Factor 179
0.4M 7 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]437,26 6,61 transcr. Factor 179
0.4M 8 D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]191,31 6,61 transcr. Factor 179
0.4M B D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]209,99 6,61 transcr. Factor 179
0.4M C D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]444,17 6,61 transcr. Factor 179
0.4M D D3ZZQ2 Protein Nfatc2 OS=Rattus norvegicus GN=Nfatc2 PE=4 SV=1 - [D3ZZQ2_RAT]183,16 6,61 transcr. Factor 179
0.3M 3 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]139,33 6,37 transcr. Factor 82
0.3M 4 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]130,88 6,37 transcr. Factor 82
0.3M 5 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]62,48 6,37 transcr. Factor 82
0.3M 6 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]155,66 6,37 transcr. Factor 82
0.3M 7 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]270,82 6,37 transcr. Factor 82
0.3M B D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]190,40 6,37 transcr. Factor 82
0.3M C D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]134,16 6,37 transcr. Factor 82
0.4M 2 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]89,56 6,37 transcr. Factor 82
0.4M 3 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]118,97 6,37 transcr. Factor 82
0.4M 4 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]256,08 6,37 transcr. Factor 82
0.4M 5 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]177,48 6,37 transcr. Factor 82
0.4M 6 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]142,17 6,37 transcr. Factor 82
0.4M 7 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]389,20 6,37 transcr. Factor 82
0.4M 8 D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]249,43 6,37 transcr. Factor 82
0.4M B D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]75,26 6,37 transcr. Factor 82
0.4M C D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]183,56 6,37 transcr. Factor 82
0.4M D D3ZU59 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 (Predicted), isoform CRA_a OS=Rattus norvegicus GN=Nfatc3 PE=4 SV=1 - [D3ZU59_RAT]118,41 6,37 transcr. Factor 82
0.4M 3 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]352,84 5,12 DNA helicase activity 44
0.4M 4 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]288,92 5,12 DNA helicase activity 44
0.3M 3 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]177,21 5,12 DNA helicase activity 44
0.3M 4 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]101,19 5,12 DNA helicase activity 44
0.3M 5 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]86,74 5,12 DNA helicase activity 44
0.4M 5 G3V817 Protein Xrcc5 OS=Rattus norvegicus GN=Xrcc5 PE=4 SV=1 - [G3V817_RAT]35,58 5,12 DNA helicase activity 44
0.4M 6 Q9EPH8 Polyadenylate-binding protein 1 OS=Rattus norvegicus GN=Pabpc1 PE=2 SV=1 - [PABP1_RAT]159,63 9,50 transcr. factor,DNA binding 22
0.3M 4 Q9EPH8 Polyadenylate-binding protein 1 OS=Rattus norvegicus GN=Pabpc1 PE=2 SV=1 - [PABP1_RAT]307,76 9,50 transcr. factor,DNA binding 22
0.4M 4 Q9EPH8 Polyadenylate-binding protein 1 OS=Rattus norvegicus GN=Pabpc1 PE=2 SV=1 - [PABP1_RAT]88,07 9,50 transcr. factor,DNA binding 22
0.4M 2 G3V8T4 DNA damage-binding protein 1 OS=Rattus norvegicus GN=Ddb1 PE=4 SV=1 - [G3V8T4_RAT]357,47 5,26 damage DNA binding 22
0.3M 2 G3V8T4 DNA damage-binding protein 1 OS=Rattus norvegicus GN=Ddb1 PE=4 SV=1 - [G3V8T4_RAT]284,88 5,26 damage DNA binding 22
0.2M D D3ZQV8 RCG47045, isoform CRA_d OS=Rattus norvegicus GN=Phf6 PE=4 SV=1 - [D3ZQV8_RAT]292,73 8,73  double-stranded DNA binding,general transcription21
0.2M 12 D3ZQV8 RCG47045, isoform CRA_d OS=Rattus norvegicus GN=Phf6 PE=4 SV=1 - [D3ZQV8_RAT]200,86 8,73  double-stranded DNA binding,general transcription21
0.2M 13 D3ZQV8 RCG47045, isoform CRA_d OS=Rattus norvegicus GN=Phf6 PE=4 SV=1 - [D3ZQV8_RAT]155,75 8,73  double-stranded DNA binding,general transcription21
0.4M 8 D3ZQV8 RCG47045, isoform CRA_d OS=Rattus norvegicus GN=Phf6 PE=4 SV=1 - [D3ZQV8_RAT]55,10 8,73  double-stranded DNA binding,general transcription21
0.2M 11 F1M1H9 Uncharacterized protein (Fragment) OS=Rattus norvegicus PE=4 SV=1 - [F1M1H9_RAT]463,16 9,69 transc. Factor HMG box 19
0.4M 11 F1M1H9 Uncharacterized protein (Fragment) OS=Rattus norvegicus PE=4 SV=1 - [F1M1H9_RAT]179,35 9,69 transc. Factor HMG box 19
0.4M 8 D3ZR08 Protein LOC100362121 OS=Rattus norvegicus GN=LOC100362121 PE=4 SV=1 - [D3ZR08_RAT]93,78 9,16 damage DNA binding 16
0.4M D D3ZR08 Protein LOC100362121 OS=Rattus norvegicus GN=LOC100362121 PE=4 SV=1 - [D3ZR08_RAT]61,07 9,16 damage DNA binding 16
0.3M D D3ZR08 Protein LOC100362121 OS=Rattus norvegicus GN=LOC100362121 PE=4 SV=1 - [D3ZR08_RAT]55,22 9,16 damage DNA binding 16
0.4M C D3ZR08 Protein LOC100362121 OS=Rattus norvegicus GN=LOC100362121 PE=4 SV=1 - [D3ZR08_RAT]50,27 9,16 damage DNA binding 16
0.3M 8 D3ZR08 Protein LOC100362121 OS=Rattus norvegicus GN=LOC100362121 PE=4 SV=1 - [D3ZR08_RAT]46,35 9,16 damage DNA binding 16
0.3M G G3V740 Homeobox protein Nkx-2.1 OS=Rattus norvegicus GN=Nkx2-1 PE=3 SV=1 - [G3V740_RAT]62,04 9,69 transcr. Factor 15
0.4M 11 G3V740 Homeobox protein Nkx-2.1 OS=Rattus norvegicus GN=Nkx2-1 PE=3 SV=1 - [G3V740_RAT]165,78 9,69 transcr. Factor 15
0.3M F G3V740 Homeobox protein Nkx-2.1 OS=Rattus norvegicus GN=Nkx2-1 PE=3 SV=1 - [G3V740_RAT]61,72 9,69 transcr. Factor 15
0.2M B O35986 Zinc finger Ran-binding domain-containing protein 2 OS=Rattus norvegicus GN=Zranb2 PE=2 SV=2 - [ZRAB2_RAT]89,14 9,89 transc. Factor zinc finger 13
0.2M 7 O35986 Zinc finger Ran-binding domain-containing protein 2 OS=Rattus norvegicus GN=Zranb2 PE=2 SV=2 - [ZRAB2_RAT]128,31 9,89 transc. Factor zinc finger 13
0.4M 1 O35986 Zinc finger Ran-binding domain-containing protein 2 OS=Rattus norvegicus GN=Zranb2 PE=2 SV=2 - [ZRAB2_RAT]62,06 9,89 transc. Factor zinc finger 13
0.4M 14 F1LP73 Uncharacterized protein OS=Rattus norvegicus PE=3 SV=1 - [F1LP73_RAT]193,26 10,46 histone,DNA binding 6
0.3M 13 F1LP73 Uncharacterized protein OS=Rattus norvegicus PE=3 SV=1 - [F1LP73_RAT]175,38 10,46 histone,DNA binding 6
0.3M 16 F1LP73 Uncharacterized protein OS=Rattus norvegicus PE=3 SV=1 - [F1LP73_RAT]141,15 10,46 histone,DNA binding 6
0.2M 2 F8WGA1 Cullin-associated NEDD8-dissociated protein 1 OS=Rattus norvegicus GN=Cand1 PE=4 SV=1 - [F8WGA1_RAT]98,61 5,83 transc. Factor 6
0.4M 2 F8WGA1 Cullin-associated NEDD8-dissociated protein 1 OS=Rattus norvegicus GN=Cand1 PE=4 SV=1 - [F8WGA1_RAT]68,41 5,83 transc. Factor 6
0.4M 8 F1LPS8 Transcriptional activator protein Pur-alpha OS=Rattus norvegicus GN=Pura PE=4 SV=1 - [F1LPS8_RAT]275,29 6,44 transcr. factor,DNA binding 6
0.4M 4 Q99PK0 Pre-mRNA-splicing factor SYF1 OS=Rattus norvegicus GN=Xab2 PE=2 SV=1 - [SYF1_RAT]76,58 6,23 transcr. Factor,damage DNA binding 3
0.4M 11 B0BN99 Hmgb3 protein OS=Rattus norvegicus GN=Hmgb3 PE=2 SV=1 - [B0BN99_RAT]72,26 8,37 transcr. Factor HMG box 2
0.4M 7 B5DFL5 Protein Sap30bp OS=Rattus norvegicus GN=Sap30bp PE=2 SV=1 - [B5DFL5_RAT]59,01 4,87 transcr. factor 2
0.4M 2 D4A8C8 Uncharacterized protein OS=Rattus norvegicus GN=Gcfc1 PE=4 SV=1 - [D4A8C8_RAT]65,22 5,67 transcr. factor 2
0.4M 4 F1SW39 PC4 and SFRS1 interacting protein 1 OS=Rattus norvegicus GN=SBP75 PE=2 SV=1 - [F1SW39_RAT]20,65 9,13 transcr. Cofactor 2
0.4M 16 Q5RK03 CDKN2AIP N-terminal-like protein OS=Rattus norvegicus GN=Cdkn2aipnl PE=3 SV=1 - [C2AIL_RAT]91,72 5,29 transcr. Actvity,DNA binding 2
Table 3: Transcription factors identified by mass spectrometry ordered according to the total number 
of peptides of each. 
The lines are divided by color: orange indicates the proteins present in the active fractions 0.4-0.3M, pink 
stands for 0.4-0.2M, violet for the proteins in 0.4M 
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From here onwards the involvement of these factors to the transcriptional regulation of the 
Pax8 promoter should be confirmed just as done previously. 
 
 
Transcript abundance of Nfatc genes identified in FRTL-5 and HeLa cells 
 
The different binding activity observed in the different extracts, may be due to the differential 
gene expression in the cell lines analyzed. 
So the first point I assessed was the differential Nfatc2/c3 gene expression in FRTL-5 versus 
HeLa cells, one of the cell lines that show no activity on the A7 sequence. 
As shown Nfatc2 mRNA is more expressed than its human counterpart expression (Fig.22), 
while Nfatc3 mRNA has roughly the same low levels of expression between the two cell lines.  
 
 
 
 
 
 
 
 
Fig.19:  Comparison of Nfatc2/c3 mRNA gene expression by qRT between HeLa and FRTL-5. 
Quantitative real time PCR was carried out using pair of primers common to all isoforms of each gene per cell line. The 
mRNA expression level was normalized to the tubulin mRNA expression level, in fold change to HeLa Nfatc2/c3 gene 
expression, mean value of technical triplicate.  
Error bars represent the error standard. 
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For this reason I went on with my work by focusing on Nfatc2 and Nfatc1 gene expression 
including some of the cell lines analyzed by DNA binding activity on A7. 
I included into the analysis the Jurkat cell line which showed activity on A7 and is reported to 
express NFAT family proteins, and the human neuroblastoma cell line SK-N-BE, one of the 
cell lines with no activity on A7. 
Both Nfatc1-Nfatc2 genes share the same trend of expression with the highest level in FRTL-
5, in comparison with a very low expression value for HeLa and SK-N-BE, while the gene 
expression in Jurkat cells stands between the two. Even if these preliminary data need to be 
confirmed at the protein level it can be stated that Nfatc1-c2 transcript expression is higher in 
those cell lines which show binding on A7. 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Comparison of Nfatc2 transcript abundance in FRTL5, Jurkat, HeLa and SK-N-BE by qRT. 
Quantitative real time PCR was carried out using pair of primers common to all isoforms of each gene per cell line. 
The mRNA expression level is the mean value of technical triplicate normalized to the tubulin mRNA expression 
level. Error bars represent the standard deviation. 
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Fig. 21: Comparison of Nfatc1 transcript abundance in FRTL5, Jurkat, HeLa and SK-N-BE by qRT. 
Quantitative real time PCR was carried out using pair of primers common to all isoforms of each gene per cell line. 
The mRNA expression level is the mean value of technical triplicate normalized to the tubulin mRNA expression 
level. Error bars represent the standard deviation. 
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DISCUSSION 
 
 
 
My thesis work has been focused on the study of an unknown DNA binding activity that 
recognize the Pax8 promoter and shows a preferential presence in differentiated thyroid cells. 
The Pax8 transcription factor has an important role in thyroid organogenesis as it, together 
with Nkx2-1, Hhex and Foxe1 transcription factors, marks a restricted number of cells in the 
ventral wall of the primitive pharynx as precursors of thyroid follicular cells.  
Each of these transcription factors is also expressed in other tissues, but such a combination is 
a unique hallmark of both differentiated thyroid follicular cells and their precursors. Studies in 
animal models have shown the relevance of these factors for thyroid development. In the 
absence of Nkx2–1, Hhex, Pax8, or Foxe1, the thyroid anlage is correctly formed but the 
subsequent thyroid morphogenesis is severely impaired. Thus, neither of this transcription 
factors is alone required for the specification of thyroid progenitors in the foregut endoderm 
and to date there are still no data available on the early events in thyroid organogenesis. 
It is well known that cell determination is a process in which a cell’s potency is progressively 
restricted during development involving both cell-autonomous mechanisms and inductive 
signals from a cell’s surroundings. Combinations of these influences result in progressive 
alterations in the gene expression patterns of embryonic cells. 
During morphogenesis, embryonic tissues sorrounding the developing thyroid become 
increasingly complex as suggested by the structure of the pharyngeal metamere; this reflects 
the complexity of the network signaling involved.  
Recent studies have in fact demonstrated the importance of the expression of some genes in 
tissues adjacent to thyroid primordium and that can influence the morphogenesis of the thyroid 
gland although they are never expressed during the development of this tissue. 
For example FGFs derived from the mesoderm evidently influence thyroid morphogenesis: 
fgf8 deficient zebrafish embryos show a severely hypoplastic thyroid (Wendl et al., 2007), in 
mice FGF8 was recently shown to stimulate the generation of endoderm progenitors 
committed to a thyroid fate (Lania et al., 2009) by means of the Tbx protein: the 
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overexpression of Fgf8 in the mesoderm partially rescues the thyroid defects observed in tbx 
null mice. 
This provides a direct proof of a central role of mesoderm in thyroid development in higher 
vertebrates. 
Among the cell-autonomous mechanisms in cell fate determination, the transcriptional 
regulation resembles some aspects of the embryonic regulatory programs, suggesting that 
studies of cells in culture may improve our understanding of embryonic development (Fagman 
2011). 
An example of this is given by the transcriptional coactivator Taz, recently shown to enhance 
in vitro the activity of Pax8 and Nkx2-1 on the thyroglobulin promoter (Di Palma et al 2009). 
Taz is expressed in coincidence with the onset of Tg biosynthesis in mouse embryonic thyroid 
at E 14.5 and in its lack Pax8 and Nkx2-1 are unable to activate the tg promoter, suggesting a 
Taz-mediated coactivation of genes at earlier stages of development. 
In general transcription factors exert their influence on the specification by cell-autonomous 
regulation of tissue specific genes; hence the study of cis-regulatory elements of thyroid 
specific selector genes would be the first step in the elucidation of the transactivating factors 
estabilishing the thyroid-specific molecular network. 
In particular during these years our research group has been focusing on the regulation of the 
pax8 gene that is the first of the four above mentioned selector genes to be expressed.  
Pax8 is also considered a master gene in the maintenance of functional differentiation in 
thyroid cells, activating transcription of thyroid specific genes such as thyroglobulin and 
thyroperoxidase which are exclusively expressed in this organ; in the tg promoter Pax8 
binding sites overlap with that of Titf-1, while in tpo promoter it was found a mutation that 
affected only Pax8 binding thus suggesting an important role for Pax8 in thyroid specific gene 
expression. 
Moreover it was demonstrated that the introduction of Pax8 in the transformed PCPy cell line 
free of thyroid specific genes, was able to reactivate their transcription (Pasca di Magliano et 
al 2000). 
Recently it has been reported that a transient overexpression of the transcription factors Nkx2-
1 and Pax8 is sufficient to direct mouse embryonic stem-cell differentiation into thyroid 
follicular cells that organize into three-dimensional follicular structures when treated with 
thyrotropin (Antonica F. et al., 2012). 
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Hence the identification of the novel thyroid specific DNA binding activity in the pax8 
promoter could elucidate the early events in thyroid commitment; we therefore carried out 
biochemical analysis on the binding complex and identified some probable candidates 
belonging to the family of transcription factors NFAT, integrating mass spectrometry data 
with bioinformatic data: NFATc2, NFATc3, NFATc1. 
The NFAT (nuclear factor of activated T cell) family of transcription factors was initially 
identified as comprising inducible nuclear factors which bound the interleukin-2 promoter in 
activated T cell (Shaw, J. P. et al. 1988).  
The family consist of five members: NFATc1- also called NFATc or NFAT2; NFATc2 - also 
called NFATp or NFAT1; NFATc3 - also called NFATx or NFAT4; NFATc4 - also called 
NFAT3 and NFAT5. 
The primordial family member is NFAT5, the only NFAT-related protein represented in the 
Drosophila genome, while NFAT1-4 does not have homologs present in invertebrates and 
appear to have emerged simultaneously early in the course of vertebrate evolution. 
These proteins are widely expressed but each of them has a different tissue specificity. 
The hallmark of NFAT members (except for NFAT5) is their regulation by Ca++ and the 
Ca++/calmodulin-dependent serine phosphatase calcineurin. NFAT proteins are 
phosphorylated and reside in the cytoplasm in resting cells; upon stimulation, they are 
dephosphorylated by calcineurin, translocate to the nucleus, and become transcriptionally 
active. The primary role for them in this pathway is the expression/repression of genes like 
tnfα, IL-2, IL-4 involved in the differentiation program of Th1/Th2. 
All members of the NFAT family share a conserved core region which consist of two tandem 
domains: a regulatory domain, the NFAT-homology region (NHR) which contains a 
transactivation domain, docking sites for calcineurin and NFAT kinases, and the REL-
homology region (RHR) which binds DNA and is evolutionary related by structure similarity 
to the Rel/NFkB family. 
However, until now no information is given on the regulation of these proteins in thyroid and 
therefore on the role that these domains, if present together, exercise in the thyroid. 
Although the redundancy in some pathways due to common DNA-binding specificities, NFAT 
members can differ in their functions through unique partner interactions and post-
translational modifications, result of further modulation by additional inputs from diverse 
signaling pathways, which affect NFAT kinases and nuclear partner proteins. 
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For example sumoylation has recently been identified as a new mechanism that regulates 
NFAT1-specific nuclear retention, in that sumoylation sites located in its C terminus are not 
conserved in other members. 
In T cell, the specific expression of IL-3 gene is partly controlled by cooperation between Oct 
and NFATp binding onto the enhancer.   
Moreover the NFAT role in cell differentiation covers many other tissues beside lymphoid 
lineage; this is in accordance with the wide expression of this family. 
Gene targeting has implicated NFATc1 in cardiac valve developmental process. Mice 
homozygous for two different single-exon deletions in the NFATc1 gene display defects in 
cardiac valve and septum formation; the cardiac failure is lethal by E13.5. (de la Pompa et al. 
1998; Ranger et al. 1998a). 
Nfatc3 -/- mutant mice exhibit skeletal muscle hypoplasia (Kegley et al. 2001) due to an 
impaired muscle development during embryogenesis. 
Nfatc3/c4 null mice die at E10.5 with vasculature patterning defects not related to the inability 
of endothelial cells to differentiate but to the failure of responding and give signals essential 
for the assembly of vessels along specific pathways (Graef et al 2001). 
To confirm the involvement of these proteins as effectors in the early events in thyroid 
commitment, I firstly carried out studies on their expression in FRTL-5 bringing Jurkat and 
HeLa cells respectively as positive and negative controls. 
These studies have reported a good expression for the transcript of NFATc1 and NFATc2 in 
FRTL-5 when compared with that of some cell lines with no binding on A7, suggesting a 
positive regulation for these genes in FRTL-5. From here it will follow the setting up of 
further experiments to confirm that these proteins actually bind the Pax8 promoter regulating 
it.  
Anyway these preliminary experiments, together with the role in development above 
mentioned, could lead us thinking of an involvement of the NFAT family to the thyroid 
commitment event as that of a tissue specific activity given by an integration of 
Ca++/calcineurin and developmental signals on NFAT transcription complexes assembled on 
the Pax8 promoter. 
 
 
 
 
42 
 
 
MATERIALS AND METHODS 
 
 
 
Cell cultures  
 
The rat thyroid FRTL-5 cell line was grown in Coon’s modified F-12 medium (Euroclone)  
supplemented with 5% v/v calf serum and a six-hormone mixture (Ambesi-Impiombato and Coon, 
1979). The human epitheloid cervix carcinoma HeLa, the dog epithelial-like kidney MDCK cell line 
and the human neuroblastoma cell line SK-N-BE were grown in Dulbecco's modified Eagle's 
medium (Euroclone) supplemented with 10% fetal calf serum (Hyclone). The human T  
lymphoblastoid cell line Jurkat was grown in RPMI 1640 (Gibco) supplemented with 10% v/v fetal 
calf serum (Hyclone). 
 
 
RNA interference 
 
FRTL-5 cells were plated (18x104) in 6-well plate and were transfected with 50 nM Gtf2i siRNA 
(4390771- s165531 life technology) and 50nM siRNA negative control (AM4611 life technology); 
INTERFERin transfection reagent (Polyplus 409-10) was used following the manufacturer’s 
protocol. Cells were harvested 96 h after transfection, proteins and total RNA were extracted. 
 
 
RNA extraction, quantitative real time RT-PCR. 
 
Total RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer’s protocol. 
For qRT-PCR the cDNA was synthetized using Quantitect Reverse Transcription kit (205-313 
Qiagen). Real time RT-PCR analysis was performed using SYBR Green PCR master mix (Applied 
Biosystem) in an iCycler-iQ real-time detection system. Reactions were carried out in triplicate. The 
specific primer sets used for real time analysis were: tubulin1a human-rattus (Fwd: 
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CAACACCTTCTTCAGTGAGAC Rev: TACATGATCTCCTTGCCAATGGT), Pax8 (Fwd: 
5’CAGCTATGCCTCTTCCGCTATT3’; Rev: 5’TGTGGCTGTAGGCATTGCC3’), NFATc2 
human (Fwd:TTCCCATCTGCAGCATCCCAG; Rev:GCTGCCTTCTGTCTCATAGTGG), 
NFATc2 rattus (Fwd: ATTCCGCTCCAGAGTCCATC Rev: CATAGGAGCCCGACTGGTTG), 
NFATc1 human (Fwd: GCCATCCTCTCCAACACCAA Rev TTCAGGATTCCGGCACAGTC), 
NFATc1 rattus (Fwd: AATAACCAGCCCCGTCCAAG Rev: GGTCAGAGCTGGCTCAAAGT ),    
Nfatc3 human (Fwd:GCCCATTATGAAACTGAAGGTAGC 
Rev:CGATCATCTGCTGTCCCAAT), NFATc3 rattus (Fwd:GGTGGCCATCCTGTTGTGAAG 
Rev: TCCAGTAATGCGATGCACCT) .Expression values are means ± SE of technical triplicates, 
normalized by the expression of tubulin1a.  
 
 
Nuclear extracts 
 
Nuclear extracts were prepared by a modification of described procedures (Civitareale D. et al 
1989). As for 100 mm dishes extraction cells were lysed starting from cells grown to near 
confluency, washed twice with ice-cold phosphate-buffered saline (PBS) and lysed in 400 ul of 
buffer I. After 10 min on ice, the cells were vortexed and sucrose restore solution was then added 
(1/10 of total volume). The homogenate was spun for 20 sec at 13.000 rpm and surnatant 
(containing cytoplasm) was removed. The nuclear pellet was resuspended in  solution IS, spun as 
above, and resuspended in 50 ul of solution II. After 30 min on ice, the nuclear suspension was spun 
at 13.000 rpm for 5 minutes. The same procedure as above for cell grown in 150 mm dishes except 
for the volumes, 2.5x greater in all steps. The nuclear proteins present in the surnatant were frozen 
in liquid nitrogen and stored in aliquots at -80°C.  
 
 
Electrophoretic mobility-shift assay 
 
Single stranded oligonucleotides (1 pmol) were end-labelled with 2ul of  [γ-32P]ATP (Perkin Elmer; 
specific radioactivity 3000 Ci/mmol) in the presence of 10 units of T4 polynucleotide kinase (New 
England BioLabs) at 37° for 1 hour and then annealed to antisense complementary sequences to 
make double-strand probes. The probes (80000 cpm) were mixed with nuclear cell extracts (4 µg) in 
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20 µl of reaction buffer containing 20 mM Tris (pH 7.5), 75 mM KCl, 1 mM dithiothreitol, 1mg/ml 
BSA, 10% glycerol, 3 ug poly (dI-dC) as a non-specific competitor, and incubated at room 
temperature for 30 min. DNA-protein complexes were resolved on a 5% (w/v) non denaturing 
polyacrylamide gel in 0.5x TBE buffer at 200 V; gels were dried and autoradiographed with 
intensifying screens at -70° from 12 to 24 hours. For supershift assays, 5µg of specific antibodies 
αGtf2i (H-58 Santa Cruz, CA), αNFAT5 (H-300 Santa Cruz, CA), αFLAG (clone M2 F3165 
SIGMA) were incubated with protein extracts for 20 min before adding the probe. 
 
 
Western Blot analysis 
 
Cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed in a buffer 
containing  Tris pH 8 50 mM, MgCl2 5 mM, NaCl 150 mM, deossicolic acid 0, 5%, SDS 0,1%, 
triton X-100 1%, and protease inhibitors cocktail (SIGMA), 1mM dithiothreitol (DTT), 1mM 
phenylmethylsulfonyl fluoride (PMSF). The protein concentration was determined by bicinchoninic 
acid protein assay (Pierce Biotechnology, Rockford, IL) and extracts were separated on NuPAGE® 
4-12% Bis Tris gels (Invitrogen) under reducing conditions and transferred to polyvinylidene 
difluoride (PVDF) membrane Immobilon P (Millipore, Bredford, MA, USA) for 1,30 hour; 
membranes were blocked 1 hour or overnight in 5% nonfat dried milk in tris buffered saline plus 
Tween 20  0, 1%.  Membranes were then hybridized with antibodies against Gtf2i (H-58 sc-28716x 
Santa Cruz, CA), NFAT5 (H-300 sc-13035x Santa Cruz, CA), tubulin (SIGMA). The filters were 
washed three times in Tris-buffered saline plus 0.1% Tween 20 before the addition of horseradish 
peroxidase-conjugated secondary antibodies for 45 min. Horseradish peroxidase was detected with 
ECL western Blot substrate (Pierce) and X-ray films (Fuji film). 
 
 
Immunodepletion 
 
For immunodepletion FRTL-5 cells were washed twice with ice-cold phosphate-buffered saline 
(PBS) and lysed in Tris pH 8 50 mM, MgCl2 5 mM, NaCl 150 mM, deossicolic acid 0, 5%, SDS 
0,1%, triton X-100 1%, and protease inhibitors cocktail (SIGMA), 1mM dithiothreitol (DTT), 1mM 
phenylmethylsulfonyl fluoride (PMSF). 1 mg of total protein extract was adjusted to a final volume 
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of 300 ul and precleared with 50 ul slurry protein A agarose beads on a rotating wheel for  20 min at 
4°C; discarded the beads the supernatant was incubated with 10ug of specific antibodies 
(monoclonal anti GTF2i WH0002969M1 SIGMA, anti NFAT5 H300 sc-13035x Santa Cruz)  for 
2h; immunocomplexes were captured by adding 50 ul slurry Protein A agarose beads and by gentle 
rocking on a rotating wheel for 1h at 4°C. Beads were collected, washed five times in lysis buffer 
and bound proteins were eluted in native state using 0.1 M glycine pH 2.7 for 5 min on ice then 
neutralized using 0,1 volume of 1M Tris-HCl pH 7.5; denaturing elution was performed using 
NuPAGE® LDS Sample Buffer and reducing agent boiling samples for five minutes. Equal volumes 
of supernatant and eluted proteins were separated by Western Blot according the above mentioned 
procedure; supernatant was resolved for DNA-protein complexes by EMSA in accordance with the 
described procedure.  
 
 
Purification procedure 
 
Nuclear extracts from FRTL-5 cell line (about 90 mg from 270 cell culture dishes of 150 mm) were 
loaded on a 2,5ml packed DEAE column (DEAE-Sepharose fast flow, GE Healthcare) at a flow rate 
of 2 ml/min, after 0.4 M to 0.3 M KCl salt dilution in buffer A (40 mM Hepes pH 7.9, 6mM MgCl2, 
0.2mM EDTA, 20% v/v glycerol, 1 mM DTT). This KCl molarity prevents proteins from being 
retained by the column thus separating them from the DNA which remains bound to the resin. The 
flow through is then loaded on 2 ml packed Blue Sepharose column (Capto Blue fast flow, GE 
Healthcare) at a flow rate of 0,5 ml/min. Retained proteins were eluted by raising the KCl 
concentration of buffer A (0.3-0.5-0.6-0.7-0.8-1-1.2M KCl). Fractions containing the activity span 
from 0.6 to 1.2 M KCl, as assessed by EMSA, were pooled and carried to 50 mM by dilution in 
buffer Z (25 mM Hepes pH 7.8, 12.5 mM MgCl2, 0.1% NP40) upon concentration on centrifugal 
filter devices  (Amicon Ultra-15). Extracts were then loaded on a 4ml slurry (2 ml packed) DNA 
affinity column (CNBr Sepharose fast flow, GE Healthcare) constructed with the multimeric A7 
oligonucleotide (see below). Retained proteins were eluted by a  5 ml linear KCl gradient (0.15-0.2-
0.3-0.4-0.5-0.75-1-1.5M KCl) and active fractions were assessed by EMSA. All fractions were 
trichloroacetic acid precipitated, resolved by SDS-PAGE 12% and Comassie colloidal stained. Lines 
corresponding to 0.2-0.3.0.4 M fractions eluted, were cut into 16 slices and 7-band, analyzed in 
duplicate by nLC-ESI-IT-MS/MS after digestion with trypsin. Research in database was made using 
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the software MASCOT (using Proteome Discoverer 1.3) of the UniProt database (Rattus) updated, 
considering significant identifications with  Mascot score > 25 and at least two different peptides 
(ISPAAM CNR of Naples, Dott. Scaloni laboratory). 
 
 
DNA affinity column 
 
Chemically synthesized and 5’ phosphorilated complementary oligonucleotides (250 ug each) with 
an extra BamHI recognition site at 5’ ends, were annealed together with 5’ [γ-32P] phosphorilated-
BamHI recognition site-forward oligonucleotides (500000 cpm) in 0.4 M NaCl, 10 mM Tris pH7.5, 
at 95°C for 5 min, 65°C for 10 min, 37°C 10 min, and room temperature for 10 min. The DNA is 
ethanol-precipitated, resuspended in H2O and subjected to ligation reaction over night at 16°C.  
DNA is then phenol-extracted, precipitated with ethanol, dried in vacuum and dissolved in water. 
Analysis of the resulting DNA by agarose gel electrophoresis typically shows oligomers of the basic 
oligodeoxynucleotide unit ranging from 3-mers to 75-mers. The DNA oligomers are covalently 
attached to CNBr Sepharose (0,5 g previously swelled in 25 ml HCl 1mM, then equilibrated in 
buffer K-phosphate 10 mM pH8 to give final 2ml packed) by mixing the DNA and resin on a 
rotating wheel over night at room temperature. After recovering the unbound DNA the unreacted 
CNBr Sepharose is inactivated by ethanolamine 1M pH 8 by mixing on a rotary shaker at room 
temperature for 2h. The resin is then washed with buffer K-phosphate 10 mM pH 8, K-phosphate 
1M pH8 and KCl 1 M and kept in storage buffer (10 mM Tris pH7.6, 0.3 M NaCl, 1mM EDTA, 
0.02% NaN3). 
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